GRPH Graphite Bio, Inc.

Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations.

$9.61  +0.79 (8.96%)
As of 12/06/2021 15:59:55 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/15/2009
Outstanding shares:  58,079,002
Average volume:  213,683
Market cap:   $515,160,748
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    38870X104
ISIN:        US38870X1046
Sedol:      BP7L2W6
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.28
PS ratio:   0.00
Return on equity:   -28.83%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy